VTX002 for Ulcerative Colitis

Recruiting in Palo Alto (17 mi)

+103 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Oppilan Pharma Ltd

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial tests if taking VTX002 regularly as a tablet is safe and effective for people with moderate to severe ulcerative colitis. The goal is to see if it can reduce symptoms and heal the gut lining.

Research Team

Snehal Naik, PhD

Principal Investigator

Ventyx Biosciences, Inc

Eligibility Criteria

This trial is for people who've had moderate to severe ulcerative colitis (UC) for at least 3 months. They must have active UC confirmed by a special camera test called endoscopy. People with other types of colitis, severe widespread colitis, Crohn's disease, or a history of certain abnormal connections in their intestines can't join.

Inclusion Criteria

Active UC confirmed by endoscopy

I was diagnosed with ulcerative colitis more than 3 months ago.

Exclusion Criteria

I have severe widespread inflammation in my colon.

I have been diagnosed with a specific type of colitis.

I have been diagnosed with Crohn's disease or have a history of fistulas related to it.

Treatment Details

Interventions

VTX002 (Unknown)

Trial OverviewThe study tests if VTX002 tablets are safe and effective when taken daily by UC patients compared to a placebo (a pill without any medicine). Participants will be randomly assigned to receive either VTX002 at two different doses or placebo and followed up for up to 36 months including various treatment phases.

Participant Groups

3Treatment groups

Experimental Treatment

Placebo Group

Group I: VTX002 Dose BExperimental Treatment1 Intervention

VTX002 Dose B tablet administered orally once daily

Group II: VTX002 Dose AExperimental Treatment1 Intervention

VTX002 Dose A tablet administered orally once daily

Group III: PlaceboPlacebo Group1 Intervention

Placebo tablet administered orally once daily